You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GA101

Showing 26 - 50 of 851
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Madison (Bendamustine, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Sep 13, 2022

CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive Trial in Atlanta, Johns Creek (Bendamustine, Obinutuzumab, Venetoclax)

Active, not recruiting
  • CCND1 Positive
  • +2 more
  • Atlanta, Georgia
  • +2 more
Nov 2, 2022

Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Zanubrutinib)

Recruiting
  • Chronic Lymphoid Leukemia
  • Aachen, Germany
  • +20 more
Oct 5, 2021

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

Leukemia Trial in Houston (Pirtobrutinib, Obinutuzumab, Venetoclax)

Not yet recruiting
  • Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Sep 7, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Austria (Venetoclax, Obinutuzumab)

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Graz, Austria
  • +5 more
Feb 15, 2022

Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1

Active, not recruiting
  • Ann Arbor Stage II Grade 1 Follicular Lymphoma
  • +12 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 18, 2022

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,

Active, not recruiting
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
  • +11 more
  • Atlanta, Georgia
  • +1 more
Apr 18, 2022

Large B-cell Lymphoma Trial in Philadelphia (mosunetuzumab, glofitamab, obinutuzumab)

Recruiting
  • Large B-cell Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jul 21, 2022

CNS B-Cell Non-Hodgkin Lymphoma Trial in United States (procedure, biological, other)

Recruiting
  • Central Nervous System B-Cell Non-Hodgkin Lymphoma
  • Cognitive Assessment
  • +2 more
  • Denver, Colorado
  • +11 more
Jun 9, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,

Recruiting
  • Grade 1 Follicular Lymphoma
  • +7 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Dec 7, 2021

Indolent Non-Hodgkin Lymphoma Trial in München (Ibrutinib, GA 101)

Active, not recruiting
  • Indolent Non-Hodgkin Lymphoma
  • München, Bavaria, Germany
    Klinikum der Universität München
May 6, 2021

Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic

Recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 30, 2021

Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Germany (Obinutuzumab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Richter's Transformation
  • Obinutuzumab
  • Bonn, Germany
  • +6 more
Dec 16, 2021

Chronic Lymphocytic Leukemia Trial in Boston, Rochester, Durham (Obinutuzumab, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +3 more
Jan 3, 2022

Marginal Zone Lymphoma Trial in Germany (Obinutuzumab)

Active, not recruiting
  • Marginal Zone Lymphoma
  • Bochum, Germany
  • +15 more
Nov 4, 2022

Mantle Cell Lymphoma Trial in Warszawa, Wroclaw (Obinutuzumab)

Terminated
  • Mantle Cell Lymphoma
  • Warszawa, Poland
  • +1 more
Dec 23, 2021

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) Trial in United States (Zanubrutinib, Obinutuzumab,

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Leukemia (SLL)
  • Evanston, Illinois
  • +7 more
Sep 9, 2022

Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Columbus (drug, biological, other)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Refractory Chronic Lymphocytic Leukemia
  • Bcl-2 Inhibitor GDC-0199
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Oct 29, 2021

Chronic Lymphocytic Leukemia Trial in Germany (Tirabrutinib, Idelalisib, Obinutuzumab)

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • Frankfurt, Brandenburg, Germany
  • +13 more
Dec 24, 2021

Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma Trial in Portland (drug, other, biological)

Completed
  • Anemia
  • +13 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Apr 29, 2021

CD20 Positive Diffuse Large B-cell Lymphoma, Elderly Unfit Patients Trial in Italy (Ga101)

Terminated
Has Results
  • CD20 Positive Diffuse Large B-cell Lymphoma
  • Elderly Unfit Patients
  • Ga101
  • Brescia, BS, Italy
  • +15 more
Nov 4, 2020

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Trial in Japan (Venetoclax, Ibrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Nagoya-shi, Aichi, Japan
  • +19 more
Jan 25, 2023

Follicular Lymphoma Patients (Phase IB), Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) Trial in

Active, not recruiting
  • Follicular Lymphoma Patients (Phase IB)
  • Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
  • Lenalidomide and GA101
  • Antwerpen, Belgium
  • +24 more
Apr 6, 2022

Chronic Lymphocytic Leukemia Trial in Germany (Tirabrutinib, Entospletinib, Obinutuzumab)

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • Aschaffenburg, Germany
  • +14 more
Dec 17, 2021